Catalent, Inc. (NYSE:CTLT) Receives Consensus Recommendation of “Hold” from Analysts

Retrieved on: 2024-09-18 15:40:31

Tags for this article:

Stock market

Equity securities

Catalent

Gene therapy

Research and development in the United States

Click the tags to see associated articles and topics

Catalent, Inc. (NYSE:CTLT) Receives Consensus Recommendation of “Hold” from Analysts. View article details on hiswai:

Excerpt

Millennium Management LLC now owns 4,079,964 shares of the company's stock worth $229,416,000 after purchasing an additional 2,299,784 shares in the ...

Article found on: www.defenseworld.net

View Original Article